MicroC3: an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells

Therapeutic Advances in Relapsed or Refractory Multiple Myeloma

(2017) Kenneth C. Anderson   Journal of the National Comprehensive Cancer Network

Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management

(2014) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

TPL2 kinase regulates the inflammatory milieu of the myeloma niche

(2014) C. Hope et al.   BLOOD

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway

(2014) Fu-Ming Zi et al.   CANCER BIOLOGY & THERAPY

The present and future role of microfluidics in biomedical research

(2014) Eric K. Sackmann et al.   NATURE

Bone marrow–on–a–chip replicates hematopoietic niche physiology in vitro

(2014) Yu-suke Torisawa et al.   NATURE METHODS

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management

(2013) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

A Preclinical Assay for Chemosensitivity in Multiple Myeloma

(2013) Z. P. Khin et al.   CANCER RESEARCH

Preclinical models of multiple myeloma: a critical appraisal

(2013) Julia Schüler et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Emerging pathways as individualized therapeutic target of multiple myeloma

(2013) Gabriella Misso et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cells, tissues, and organs on chips: challenges and opportunities for the cancer tumor microenvironment

(2013) Edmond W. K. Young   Integrative Biology

Macrophages in multiple myeloma: emerging concepts and therapeutic implications

(2013) Fotis Asimakopoulos et al.   LEUKEMIA & LYMPHOMA

Tumour heterogeneity in the clinic

(2013) Philippe L. Bedard et al.   NATURE

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS™ Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy

(2013) Marina Ferrarini et al.   PLoS One

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Clinical Translation in Multiple Myeloma: From Bench to Bedside

(2013) Jacob Laubach et al.   SEMINARS IN ONCOLOGY

Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules

(2013) E Leich et al.   Blood Cancer Journal

A perspective on paper-based microfluidics: Current status and future trends

(2012) Xu Li et al.   Biomicrofluidics

Microscale functional cytomics for studying hematologic cancers

(2012) E. W. K. Young et al.   BLOOD

Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells

(2012) Jaehyup Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

(2012) Marina Bolzoni et al.   EXPERIMENTAL HEMATOLOGY

Current Status of Methods to Assess Cancer Drug Resistance

(2012) Theodor H. Lippert et al.   International Journal of Medical Sciences

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular mechanisms of effectiveness of novel therapies in multiple myeloma

(2012) Giada Bianchi et al.   LEUKEMIA & LYMPHOMA

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

(2012) Yuan Xiao Zhu et al.   LEUKEMIA & LYMPHOMA

Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?

(2012) Heinz Ludwig et al.   LEUKEMIA RESEARCH

Role of carfilzomib in the treatment of multiple myeloma

(2012) Rashid Z Khan et al.   Expert Review of Hematology

How "immunomodulatory" are IMIDs?

(2011) C. S. Mitsiades   BLOOD

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

(2011) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy

(2011) S Sinha et al.   LEUKEMIA

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

(2011) T Calimeri et al.   LEUKEMIA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteasome inhibitors in cancer therapy

(2011) Lisa J. Crawford et al.   Journal of Cell Communication and Signaling

Microfluidic Platforms for Single-Cell Analysis

(2010) Richard N. Zare et al.   Annual Review of Biomedical Engineering

Expanding the Available Assays: Adapting and Validating In-Cell Westerns in Microfluidic Devices for Cell-Based Assays

(2010) Amy L. Paguirigan et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

(2010) B. Nair et al.   BLOOD

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

(2010) Donna E. Reece et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Fundamentals of microfluidic cell culture in controlled microenvironments

(2010) Edmond W. K. Young et al.   CHEMICAL SOCIETY REVIEWS

Microfluidic platform for chemotaxis in gradients formed by CXCL12 source-sink cells

(2010) Yu-suke Torisawa et al.   Integrative Biology

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

(2010) Stephanie Markovina et al.   Molecular Cancer

Cellular observations enabled by microculture: paracrine signaling and population demographics

(2009) Maribella Domenech et al.   Integrative Biology

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

(2009) Shaji K. Kumar et al.   MAYO CLINIC PROCEEDINGS

Using a Microfluidic Device for High-Content Analysis of Cell Signaling

(2009) R. Cheong et al.   Science Signaling

A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma

(2008) J. Kirshner et al.   BLOOD

Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells

(2008) S. Markovina et al.   MOLECULAR CANCER RESEARCH